

FOR IMMEDIATE RELEASE

AMNEAL ADDS FOUR NEW PRODUCTS TO ITS GROWING PORTFOLIO

Much-anticipated generic for Namenda® IR ready to deliver patient savings

Bridgewater, New Jersey (USA), July 17, 2015 – Amneal Pharmaceuticals has launched four new products since June, 2015. On July 13, the company obtained FDA approval for its tobramycin inhalation solution (a generic equivalent for Tobi® inhalation solution); it is the first inhalation solution formulation offered by Amneal. On July 11th, Amneal started shipping memantine HCl immediate release tablets in 5 mg and 10 mg strengths. This product is one of the first generic equivalents to Namenda® on the market.

Earlier in June, Amneal launched temozolomide capsules (AB-rated to Temodar®) in six different strengths along with divalproex sodium extended release (AB-rated to Depakote® ER) in 250 mg and 500 mg tablets.

"We developed memantine at a customer's request. For some time, patients and payers have been eagerly awaiting availability of this generic product, and now we are pleased to be one of the first manufacturers to bring it to market," explains Amneal Co-CEO & Chairman Chirag Patel. "It's one of those products that brings value to everyone in the healthcare supply chain: our customers, the patients, and the payers. Tobramycin is extremely exciting for us in that it's a new dosage form for Amneal—proof we're delivering the varied portfolio we committed to offering our customers."

Visit the Amneal product catalog at amneal.com for more information. Full prescribing information, for divalproex sodium can be found at

<https://prd02.apsiva.net/210/GenericCategory/DivalproexSodiumER-pi.pdf>.

About Amneal Pharmaceuticals LLC

Amneal Pharmaceuticals LLC is a global supplier of generic pharmaceuticals, vertically-integrated across the entire supply chain from R&D to finished goods. Since its inception in 2002, Amneal has invested extensively in R&D resources, manufacturing infrastructure, and strategic expansion opportunities—all contributing to its significant growth. The Company prides itself on its unwavering commitment to quality, strong business relationships, and innovative approach to maximizing value. Amneal is privately-held with U.S. headquarters in Bridgewater, New Jersey and international headquarters in Zug, Switzerland. For more information, please visit www.amneal.com.

All trademarks are property of their respective owners.

CONTACTS:

Jim Luce
Executive Vice President, Sales & Marketing
Amneal Pharmaceuticals LLC
M: 949.500.5756
jim@amneal.com
www.amneal.com

Cheryl Lechok
President
Cheryl Lechok Communications, LLC
Dir: 203-961-9280
M: 203-613-1506
clechok@optonline.net